Drug
Lanraplenib
Lanraplenib: highest development phase Phase 2, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lanraplenib NCT03100942 | Phase 2 | Sjogren's Syndrome |
Latest
No recent events.
Follow Lanraplenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.